I am a drug discovery scientist with a passion for identifying and investing in the most promising biotech companies.

I’m deeply interested in drug discovery and the application of quantitative science to help discover new therapies and medicines. I am currently in Early Discovery scientist at Bristol Myers Squibb in San Diego and also serve as a Dean’s Invited Lecturer at the University of Maryland, School of Pharmacy.

Before joining Bristol Myers Squibb, I gained experience in biotech by co-founding ViRelieve, a company focused on developing antiviral therapeutics, and later worked as a scientist at the Chan Zuckerberg Biohub in San Francisco. Prior to entering industry, my academic research at Stanford University focused on understanding the structure and function of biological macromolecules.

I am fascinated by biotech companies — they sit at the cutting edge of healthcare, developing the medicines and therapies of tomorrow. My passion for investing in the most promising biotech companies led me to co-found the Mythos Biotechnology Investment Fund at Stanford, where I analyzed early-stage biotech companies and conducted valuation analyses from an investor's perspective.

Although I’ve since left Mythos, I remain committed to identifying and investing in what I believe are the most promising biotech companies and contributing, in my own way, to their mission of transforming our lives.